,
,NR606 Week 8 Final Exam Due 26 April 2026 Diagnosis and
Management in Psychiatric-Mental Health II Practicum -PMHNP- 1-75
ACTUAL EXAM QUESTIONS AT Chamberlain University..pdf
Course: Diagnosis and Management in Psychiatric-Mental Health II
Practicum – PMHNP
Institution: Chamberlain University
Exam Date: 26 April 2026
Format: 75 Multiple-Choice Questions with Verified Answers and Detailed
Rationales
Core Domains
• Attention-Deficit/Hyperactivity Disorder (ADHD): Diagnosis,
Pharmacological Management, and Monitoring
• Post-Traumatic Stress Disorder (PTSD): Assessment, Evidence-
Based Psychotherapies, and Pharmacotherapy
• Bipolar Disorder: Differential Diagnosis, Mood Stabilizers, and
Atypical Antipsychotics
• Major Depressive Disorder: Treatment-Resistant Depression,
Augmentation Strategies, and Antidepressant Selection
• Eating Disorders: Anorexia Nervosa, Bulimia Nervosa, Binge-Eating
Disorder, and Medical Complications
• Disruptive, Impulse-Control, and Conduct Disorders: Diagnosis and
Behavioral Interventions
• Substance Use Disorders: Screening, Brief Intervention, and Referral
to Treatment (SBIRT)
• Child and Adolescent Mental Health: Developmental Considerations,
Psychopharmacology, and Monitoring
, Section One: ADHD – Diagnosis and Pharmacological Management
Question 1
A 9-year-old male is diagnosed with ADHD, predominantly hyperactive-
impulsive type. Which of the following is the first-line pharmacological
treatment according to current clinical guidelines?
A. Atomoxetine (Strattera)
B. Fluoxetine (Prozac)
C. Guanfacine (Intuniv)
D. Methylphenidate (Ritalin)
Answer: D. Methylphenidate (Ritalin)
Rationale: Stimulants like methylphenidate are considered first-line
treatments for pediatric ADHD due to their high efficacy rates in reducing
core symptoms. Non-stimulants like atomoxetine are typically reserved for
patients who do not tolerate stimulants or have a history of substance
abuse. It is essential for the PMHNP to monitor growth and cardiovascular
health throughout the duration of stimulant therapy.
Question 2
A PMHNP is evaluating a 9-year-old child for ADHD. The child's teacher
reports difficulty sustaining attention, frequent careless mistakes, and
trouble organizing tasks. The child's parent reports similar difficulties at
home. Which of the following is the most important next step in the
diagnostic process?
A. Initiate stimulant therapy immediately
B. Obtain rating scales from both the teacher and parent
C. Order an EEG to rule out seizure disorder
D. Refer the child for neuropsychological testing
Answer: B. Obtain rating scales from both the teacher and parent
Rationale: The diagnostic process for ADHD requires symptom
assessment across multiple settings using validated rating scales (e.g.,
Vanderbilt, Conners) completed by both parents and teachers. Stimulant
,NR606 Week 8 Final Exam Due 26 April 2026 Diagnosis and
Management in Psychiatric-Mental Health II Practicum -PMHNP- 1-75
ACTUAL EXAM QUESTIONS AT Chamberlain University..pdf
Course: Diagnosis and Management in Psychiatric-Mental Health II
Practicum – PMHNP
Institution: Chamberlain University
Exam Date: 26 April 2026
Format: 75 Multiple-Choice Questions with Verified Answers and Detailed
Rationales
Core Domains
• Attention-Deficit/Hyperactivity Disorder (ADHD): Diagnosis,
Pharmacological Management, and Monitoring
• Post-Traumatic Stress Disorder (PTSD): Assessment, Evidence-
Based Psychotherapies, and Pharmacotherapy
• Bipolar Disorder: Differential Diagnosis, Mood Stabilizers, and
Atypical Antipsychotics
• Major Depressive Disorder: Treatment-Resistant Depression,
Augmentation Strategies, and Antidepressant Selection
• Eating Disorders: Anorexia Nervosa, Bulimia Nervosa, Binge-Eating
Disorder, and Medical Complications
• Disruptive, Impulse-Control, and Conduct Disorders: Diagnosis and
Behavioral Interventions
• Substance Use Disorders: Screening, Brief Intervention, and Referral
to Treatment (SBIRT)
• Child and Adolescent Mental Health: Developmental Considerations,
Psychopharmacology, and Monitoring
, Section One: ADHD – Diagnosis and Pharmacological Management
Question 1
A 9-year-old male is diagnosed with ADHD, predominantly hyperactive-
impulsive type. Which of the following is the first-line pharmacological
treatment according to current clinical guidelines?
A. Atomoxetine (Strattera)
B. Fluoxetine (Prozac)
C. Guanfacine (Intuniv)
D. Methylphenidate (Ritalin)
Answer: D. Methylphenidate (Ritalin)
Rationale: Stimulants like methylphenidate are considered first-line
treatments for pediatric ADHD due to their high efficacy rates in reducing
core symptoms. Non-stimulants like atomoxetine are typically reserved for
patients who do not tolerate stimulants or have a history of substance
abuse. It is essential for the PMHNP to monitor growth and cardiovascular
health throughout the duration of stimulant therapy.
Question 2
A PMHNP is evaluating a 9-year-old child for ADHD. The child's teacher
reports difficulty sustaining attention, frequent careless mistakes, and
trouble organizing tasks. The child's parent reports similar difficulties at
home. Which of the following is the most important next step in the
diagnostic process?
A. Initiate stimulant therapy immediately
B. Obtain rating scales from both the teacher and parent
C. Order an EEG to rule out seizure disorder
D. Refer the child for neuropsychological testing
Answer: B. Obtain rating scales from both the teacher and parent
Rationale: The diagnostic process for ADHD requires symptom
assessment across multiple settings using validated rating scales (e.g.,
Vanderbilt, Conners) completed by both parents and teachers. Stimulant
